Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The 6th Annual Oncology Student Symposium was held at St Anne’s College, for the second time, on Monday, 9 July.

© Luana Campos Soares
Prize cover image: “In vivo brain electroporation of nuclear GFP and cytoplasmic tdTomato showed migration of neural stem cells from the subventricular zone following differentiation into glial cells (oligodendrocytes/astrocytes)” - Luana Campos Soares.

The day went really well, and the only complaint about the weather was that it was a bit stuffy in the marquee! Second year students gave their talks in the - thankfully air-conditioned - Mary Ogilvie lecture theatre; and first years presented their posters in the marquee on the lawn in St Anne's Quad. The standard was again agreed to be very high, with clear and confident talks and eye-catching posters which were eloquently explained.


The prizes for the four categories were awarded as follows:

The front cover Image Prize went to Luana Campos Soares (Eric O'Neill and Francis Szele Group) - for the second year running - with "The OLIG-ator" (It was judged blind, so this was complete chance!)

The First Year Poster Presentation Prize went to Richard Baugh (Len Seymour Group) with "Enhancing glioblastoma oncolytic virotherapy with locally delivered macrophage activators" Runners up were Linda van Bijsterveldt (Tim Humphrey and Kate Vallis Group) and Rosalin Cooper (Ben Fairfax and Mark Middleton Group).

The Second Year Oral Presentation Prize was won by Sam Hume (Grigory Dianov and Kristijan Ramadan Group) with "NUCKS nurtures neoplasms". Second place was Timo Reisländer (Madalena Tarsounas Group) and joint third place went to Sally Frost (Len Seymour group and Tzveta Pokrovska (Len Seymour Group).

Best Question Prize during the oral presentations went to Egon Jacobus (Len Seymour Group).

Congratulations to all the prize winners.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.